Logo

Vertex's Kaftrio (ivacaftor/tezacaftor/elexacaftor) + Ivacaftor Receives CHMP's Positive Opinion for the Treatment of Cystic Fibrosis in Children Aged 6 to 11

Share this

Vertex's Kaftrio (ivacaftor/tezacaftor/elexacaftor) + Ivacaftor Receives CHMP's Positive Opinion for the Treatment of Cystic Fibrosis in Children Aged 6 to 11

Shots:

  • The EMA's CHMP has adopted a positive opinion for the label extension of Kaftrio in combination with ivacaftor to treat CF in patients aged 6 to11 yrs. who have at least one F508del mutation in a CFTR gene
  • The combination therapy showed improvements in lung function, sweat chloride & respiratory symptoms, safety & tolerability profile were consistent with that observed in patients aged =12yrs.
  • Kaftrio + ivacaftor is approved in the EU for the treatment of CF in patients aged =12yrs. who have at least one copy of the F508del mutation in the CFTR gene

Ref: Businesswire | Image: Vertex

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions